U.S. Dept. of Veterans Affairs began COVID-19 vaccinations at 128 additional sites
On Dec. 21, 2020, the U.S. Dept. of Veterans Affairs (VA) announced that it had begun COVID-19 vaccinations…
On Dec. 21, 2020, the U.S. Dept. of Veterans Affairs (VA) announced that it had begun COVID-19 vaccinations…
On Dec. 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices…
On Dec. 18, 2020, the FDA issued an emergency use authorization (EUA) for the second vaccine for the…
On Dec. 18, 2020, Moderna announced that the European Commission (EC) had exercised its option to purchase an…
On Dec. 18, 2020, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 18, 2020, Moderna announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on…
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
On Dec. 14, 2020, the U.S. Dept. of Veterans Affairs (VA) announced that the New Orleans and Bedford,…
On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…
On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 10, 2020, Moderna announced that the first adolescent participants had been dosed in the Phase 2/3…
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsys Anti-SARS-CoV-2 S antibody test…
On Dec. 8, 2020, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 4.5…
On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20…
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
On Nov. 25, 2020, Moderna announced that the European Commission (EC) has approved an agreement to secure 80…
On Nov. 20, 2020, researchers at the Broad Institute of MIT and Harvard announced they had developed a…
On Nov. 17, 2020, Moderna announced a supply agreement with the government of the United Kingdom (UK) to…
On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…
On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…
On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
On Nov. 9, 2020, Ultragenyx announced that it planned to build a new large-scale gene therapy manufacturing facility…
On Nov. 6, 2020, in a study published in Cell, the researchers identified antiviral defense genes that the…
On Oct. 29, 2020, AquaBounty Technologies announced that it had identified Mayfield, Kentucky as the potential location for…